KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Long-Term Debt Repayments (2017 - 2025)

Teva Pharmaceutical Industries' Long-Term Debt Repayments history spans 9 years, with the latest figure at $444.0 million for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Debt Repayments changed N/A year-over-year to $444.0 million, compared with a TTM value of $4.1 billion through Dec 2025, up 150.58%, and an annual FY2025 reading of $4.1 billion, up 150.58% over the prior year.
  • Long-Term Debt Repayments for Q3 2025 was $444.0 million at Teva Pharmaceutical Industries, down from $2.3 billion in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $5.2 billion in Q4 2021, with the low at $296.0 million in Q2 2022.
  • Average Long-Term Debt Repayments over 5 years is $1.5 billion, with a median of $978.0 million recorded in 2023.
  • Year-over-year, Long-Term Debt Repayments plummeted 86.32% in 2022 and then skyrocketed 173.97% in 2023.
  • Tracing TEVA's Long-Term Debt Repayments over 5 years: stood at $5.2 billion in 2021, then crashed by 86.32% to $708.0 million in 2022, then surged by 41.24% to $1.0 billion in 2023, then tumbled by 31.5% to $685.0 million in 2024, then tumbled by 35.18% to $444.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Long-Term Debt Repayments are $444.0 million (Q3 2025), $2.3 billion (Q2 2025), and $1.4 billion (Q1 2025).